Amgen v. Hospira Pegfilgrastim Case Stayed Pending Potential Summary Judgment Practice
By EsqSocial Corporation 22/06/21
On June 16, 2021, the District Court for the District of Delaware issued a claim construction order construing a key term in the ongoing patent dispute between Amgen and Hospira over Hospira’s proposed biosimilar of Amgen’s Neulasta® (pegfilgrastim). In the Order, the Court construed the term “between about 0.1 M and about 1.0” to have “its plain and ordinary meaning (that is, ‘between approximately 0.1 M and approximately 1.0 M’) and is not a functional limitation.”...
By: Goodwin